The company is the only biopharma focused exclusively on the development and commercialisation of new treatment options for people with hemophilia.
Butler has more than 20 years experience in the field of commercialisation for innovative therapies.
He replaces Michael Griffith, who will become chief scientific officer, and will remain as president at Inspiration.
Our weekly round-up of the bright young things and big cheeses in pharmaceuticals.
The latest changes at Bayer, biopharma, and the winner of Professional Woman of the Year in this...
This week's pharmaceutical changes begin with the election of Reuters' head to the Board of Pfizer.